Current and historical daily PE Ratio for KRYS (
Krystal Biotech Inc
) from 2017 to May 29 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Krystal Biotech stock (KRYS) PE ratio as of May 29 2024 is 82.8.
More Details
Krystal Biotech Inc (KRYS) PE Ratio (TTM) Chart
Krystal Biotech Inc (KRYS) PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
Total 1238
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Krystal Biotech PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-29 | 83.2 | 2024-03-25 | NaN |
| 2024-05-28 | 84.6 | 2024-03-22 | NaN |
| 2024-05-24 | 86.6 | 2024-03-21 | NaN |
| 2024-05-23 | 87.0 | 2024-03-20 | NaN |
| 2024-05-22 | 90.0 | 2024-03-19 | NaN |
| 2024-05-21 | 88.7 | 2024-03-18 | NaN |
| 2024-05-20 | 87.5 | 2024-03-15 | NaN |
| 2024-05-17 | 87.3 | 2024-03-14 | NaN |
| 2024-05-16 | 87.1 | 2024-03-13 | NaN |
| 2024-05-15 | 86.8 | 2024-03-12 | NaN |
| 2024-05-14 | 84.8 | 2024-03-11 | NaN |
| 2024-05-13 | 82.3 | 2024-03-08 | NaN |
| 2024-05-10 | 82.3 | 2024-03-07 | NaN |
| 2024-05-09 | 84.4 | 2024-03-06 | NaN |
| 2024-05-08 | 83.9 | 2024-03-05 | NaN |
| 2024-05-07 | 86.0 | 2024-03-04 | NaN |
| 2024-05-06 | 83.5 | 2024-03-01 | NaN |
| 2024-05-03 | 85.7 | 2024-02-29 | NaN |
| 2024-05-02 | 85.2 | 2024-02-28 | NaN |
| 2024-05-01 | 84.9 | 2024-02-27 | NaN |
| 2024-04-30 | 81.5 | 2024-02-26 | NaN |
| 2024-04-29 | 84.0 | 2024-02-23 | NaN |
| 2024-04-26 | 83.5 | 2024-02-22 | NaN |
| 2024-04-25 | 82.8 | 2024-02-21 | NaN |
| 2024-04-24 | 84.6 | 2024-02-20 | NaN |
| 2024-04-23 | 86.2 | 2024-02-16 | NaN |
| 2024-04-22 | 83.6 | 2024-02-15 | NaN |
| 2024-04-19 | 84.3 | 2024-02-14 | NaN |
| 2024-04-18 | 87.2 | 2024-02-13 | NaN |
| 2024-04-17 | 90.2 | 2024-02-12 | NaN |
| 2024-04-16 | 90.5 | 2024-02-09 | NaN |
| 2024-04-15 | 90.3 | 2024-02-08 | NaN |
| 2024-04-12 | 92.3 | 2024-02-07 | NaN |
| 2024-04-11 | 95.7 | 2024-02-06 | NaN |
| 2024-04-10 | 93.5 | 2024-02-05 | NaN |
| 2024-04-09 | 95.6 | 2024-02-02 | NaN |
| 2024-04-08 | 96.0 | 2024-02-01 | NaN |
| 2024-04-05 | 95.8 | 2024-01-31 | NaN |
| 2024-04-04 | 94.9 | 2024-01-30 | NaN |
| 2024-04-03 | 94.6 | 2024-01-29 | NaN |
| 2024-04-02 | 94.1 | 2024-01-26 | NaN |
| 2024-04-01 | 93.7 | 2024-01-25 | NaN |
| 2024-03-28 | 94.6 | 2024-01-24 | NaN |
| 2024-03-27 | NaN | 2024-01-23 | NaN |
| 2024-03-26 | NaN | 2024-01-22 | NaN |
Krystal Biotech Inc (KRYS) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Krystal Biotech Inc
NAICS : 325412
SIC : 2836
ISIN : US5011471027
Description
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers